AmpliPhi BioSciences Corp, which is developing new antibacterial therapies, has reached an agreement with funders to raise $18 million in a private share placement to support development of therapies that target Gram-negative bacterial infections.
AmpliPhi BioSciences Corp, which is developing new antibacterial therapies, has reached an agreement with funders to raise $18 million in a private share placement to support development of therapies that target Gram-negative bacterial infections.